FDA, Biosimilar and Insulin
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can increase patient access to safe and effective treatment options.
A teenage patient has become the first in the UK, a hospital said, to receive what medics call a ground-breaking new drug for ...
NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...
A young patient identified by the ELSA study as having early stages of Type 1 Diabetes, has received treatment to delay the ...
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...
News Medical on MSN3d
Adrenomedullin hormone as key driver of insulin resistance in obesity-linked type 2 diabetesResearchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback